Precision BioSciences, Cellectis Settle Genome Engineering IP Dispute | GenomeWeb

NEW YORK (GenomeWeb News) – Precision BioSciences and Cellectis announced Thursday that they have settled patent litigation related to genome engineering technology and have agreed to cross-license certain patents.

The firms have been involved in litigation against each other for several years and they have filed multiple suits against each other over patents covering genome engineering and gene editing technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.